Results 11 to 20 of about 11,697 (224)
Interleukin-34 as a Robust Predictor of No-Reflow Phenomenon in ST-Elevation Myocardial Infarction: Insights into Inflammatory Mechanisms and Clinical Implications [PDF]
Gazi Medical JournalObjective: ST-elevation myocardial infarction (STEMI) poses a significant challenge despite advances in reperfusion strategies. The “no-reflow” phenomenon, characterized by inadequate microvascular blood flow restoration following successful ...
Mehdi Karasu +2 more
doaj +2 more sources
A Practical Method for No-Reflow Treatment [PDF]
Case Reports in Cardiology, 2016 No-reflow is an undesirable result of percutaneous coronary interventions. Vasoactive drug administration at the distal part of the coronary artery is suggested as a therapeutic option for no-reflow treatment.
Mustafa Cetin +5 more
doaj +3 more sources
Eurasian Journal of MedicineBackground: In this study, we sought to examine the statistical association of plasma osmolarity with noreflow development in patients with ST-segment elevation myocardial infarction (STEMI) who were treated with primary percutaneous coronary ...
Şerif Hamideyin , İnanç Artaç
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2016 Le Wang,1 Gang Liu,1 Jun Liu,1 Mingqi Zheng,1 Liang Li2 1Department of Cardiology, The First Hospital of Hebei Medical University, 2Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic ...
Wang L, Liu G, Liu J, Zheng M, Li L
doaj +1 more source
reflow-project/weloop-bonfire: Reflow pilots release candidate (Bonfire comp)
, 2022 WeLoop is the first client web application developed for ReflowOS. It is a modular front-end framework intended to be used as a base for Reflow pilots to build their own ReflowOS front end interfaces customised for their unique business use cases ...
Alex Castaño +14 more
core +1 more source
BMC Cardiovascular Disorders, 2020 Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of
Nian-Peng Song +5 more
doaj +1 more source
Comparison of RCHA2DS2-VASc Score and CHA2DS2-VASc Score for Prediction of No-Reflow Phenomenon in Patients with ST-Segment Elevation Myocardial Infarction undergoing Primary Percutaneous Coronary Intervention. [PDF]
Al-Azhar International Medical Journal, 2023 Background: During primary PCI, about 95% of blocked coronary vessels are reopened. Therefore, it is the best applicable reperfusion strategy for acute STEMI.
Ahmed Ibrahim Elsherif +2 more
doaj +1 more source
Scientific Reports, 2022 In patients with acute ST-elevation myocardial infarction (STEMI), it is essential to restore myocardial perfusion as soon as possible. However, a considerable proportion of patients have no-reflow.
De-Gang Mo +3 more
doaj +1 more source
Global Heart, 2022 Background: Stress hyperglycemia is a common finding during acute myocardial infarction and associated with poor prognosis. To reduce the occurrence of no-reflow, prognostic factors must be identified before primary percutaneous coronary intervention ...
Mohamed Khalfallah +2 more
doaj +1 more source
Journal of Interventional Cardiology, 2021 Objectives. To evaluate the predictive value of target lesion SYNTAX score (TL-SS) for no-reflow in the patients with acute myocardial infarction undergoing urgent percutaneous coronary intervention (PCI). Background.
Guofeng Gao +7 more
doaj +1 more source